DexCom — Jul 25, 2025 release

“In the second half of 2025, we look forward to continuing our commercial momentum while advancing our product portfolio with the highly-anticipated launch of our Dexcom G7 15 Day System.” 2025 Annual Guidance Dexcom is raising fiscal year 2025 guidance for Revenue, and reiterating guidance for Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin at the following levels: • Revenue of $4.600 - $4.625 billion (14-15% growth) • Non-GAAP Gross Profit Margin of approximately 62% • Non-GAAP Operating Margin of approximately 21% • Adjusted EBITDA Margin of approximately 30% CEO Succession Effective January 1, 2026 Dexcom today also announced the promotion of Jake Leach to CEO and to the Dexcom Board of Directors, effective January 1, 2026. Current CEO Kevin Sayer will continue to work closely with Jake during the transition period and will remain executive chairman of the board of directors at the point of transition. “Today’s announcement of Jake’s transition to the role of chief executive officer reflects the Board’s comprehensive succession planning and their confidence in Jake’s leadership throughout his tenure. We are confident that he is the right leader to build on Dexcom’s momentum and extend the company’s growth well into the future,” said Kevin Sayer. 1 Second quarter 2025 organic revenue was $1.151 billion and excludes $6.2 million of foreign exchange impact. Second quarter 2024 reported revenue included $0.2 million of non-CGM revenue subsequently divested in the following twelve months. “I am humbled and excited to transition into the CEO role at this critical time in Dexcom’s history,” said Jake Leach. “I look forward to leading our incredible teams as we advance access to our technology to more people around the world, empowering bette